Hormonal
Initiation of testosterone therapy (TT) in men aged 65 years and older is associated with a significantly increased risk of non-fatal myocardial infarction within the first 90 days of prescription.
If you are a man over 65 starting testosterone therapy, be aware that your risk of a heart attack is roughly doubled in the first three months. This risk is highest in men with existing heart disease. Discuss this risk with your doctor, who may monitor you more closely or consider alternative treatments if you have significant cardiovascular history.
Among men aged 65 years and older, we observed a two-fold increase in the risk of MI in the 90 days after filling an initial TT prescription... In men aged 65 years and older the RR was 2.19 (1.27, 3.77)
Why this rating
Observational cohort study using administrative claims data; while large and using robust statistical methods (doubly robust estimation), it lacks the controlled conditions of an RCT.
Source
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
William D. Finkle et al. · PLoS ONE · 2014
DOI 10.1371/journal.pone.0085805
More from this paper
- Initiation of testosterone therapy (TT) in men under 65 years with a pre-existing history of heart disease is associated with a significantly increased risk of non-fatal myocardial infarction within the first 90 days of prescription.Moderate
- Testosterone therapy (TT) does not significantly increase the risk of non-fatal myocardial infarction in men under 65 years without a history of heart disease.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →